From Name

From Email

To Name

To Email

Message

Azacitidine + venetoclax combo benefits older patients with AML

from Medscape

Azacitidine + venetoclax combo benefits older patients with AML Medscape For older patients with acute myeloid leukemia who are not eligible for chemotherapy, adding venetoclax to azacitidine significantly improved overall survival, complete remission and other outcomes when compared with azacitidine alone. These results come from the phase 3 VIALE-A trial, published recently in The New England Journal of Medicine. READ MORE

more